Drugs & Aging

, Volume 12, Issue 5, pp 349–360 | Cite as

Urinary Incontinence in the Elderly

Causes and Treatment Options
  • Samer Z. Nasr
  • Joseph G. Ouslander
Review Article Drug Therapy


Urinary incontinence is a prevalent and distressing condition that affects >30% of elderly individuals. A wide variety of treatment modalities is available, and can be effective in reducing or eliminating the symptoms and adverse consequences of urinary incontinence. Pharmacological therapy is an important component of the successful management of this condition, but the agents currently used do not act selectively on the lower urinary tract. Adverse effects of drug treatment are common, and are especially problematic in the elderly. A careful assessment of the type of urinary incontinence and the institution of a rational management programme are the keys to improvement or even cure in patients with this condition.


Adis International Limited Urinary Incontinence Benign Prostatic Hyperplasia Lower Urinary Tract Stress Incontinence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Herzog AR, Fultz NH. Prevalence and incidence of urinary incontinence in community-dwelling populations. J Am Geriatr Soc 1990; 38(3): 273–81PubMedGoogle Scholar
  2. 2.
    Mohide EA. The prevalence and scope of urinary incontinence. Clin Geriatr Med 1986; 2: 639–55PubMedGoogle Scholar
  3. 3.
    Ouslander JG, Kane RL, Abrass IB. Urinary incontinence in elderly nursing home residents. JAMA 1982; 248: 1194–8PubMedCrossRefGoogle Scholar
  4. 4.
    Resnick NM, Yalla SV, Laurino E. The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med 1989; 320(1): 1–7PubMedCrossRefGoogle Scholar
  5. 5.
    Thomas TM, Plymat KR, Blannin J, et al. Prevalence of urinary incontinence. BMJ 1980 Nov; 281(6250): 1243–5PubMedCrossRefGoogle Scholar
  6. 6.
    Hu TW. Impact of urinary incontinence on health-care costs. J Am Geriatr Soc 1990; 38(3): 292–5PubMedGoogle Scholar
  7. 7.
    Ouslander JG, Morishita L, Blaustein J, et al. Clinical, functional, and psychosocial characteristics of an incontinent nursing home population. J Gerontol 1987; 42(6): 631–7PubMedGoogle Scholar
  8. 8.
    Noelker LS. Incontinence in elderly cared for by family. Gerontologist 1987; 27(2): 194–200PubMedCrossRefGoogle Scholar
  9. 9.
    Schnelle JF, Traughber B, Sowell VA, et al. Prompted voiding treatment of urinary incontinence in nursing home patients: a behavior management approach for nursing home staff. J Am Geriatr Soc 1989; 37(11): 1051–7PubMedGoogle Scholar
  10. 10.
    Schnelle JF, Sowell VA, Hu TW, et al. Reduction of urinary incontinence in nursing homes: does it reduce or increase costs? J Am Geriatr Soc 1988; 36(1): 34–9PubMedGoogle Scholar
  11. 11.
    Wein AJ. Neuromuscular dysfunction of the lower urinary tract. In: Walsh PC, Retik AB, Stamey TA, et al., editors. Campbell’s urology. 6th ed. Philadelphia: Saunders, 1992: 573–642Google Scholar
  12. 12.
    Fantl JA, Wyman JF, McClish DK, et al. Urinary incontinence in community-dwelling women: clinical, urodynamic and severity characteristics. Am J Obstet Gynecol 1990; 162(4): 946–51PubMedGoogle Scholar
  13. 13.
    Abrams P, Blaivas JG, Stanton SL, et al. Standardization of terminology of lower urinary tract function. Neurourol Urodyn 1988; 7: 403–27CrossRefGoogle Scholar
  14. 14.
    Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function: an unrecognized but common cause of incontinence in elderly patients. JAMA 1987; 257: 3076–81PubMedCrossRefGoogle Scholar
  15. 15.
    Staskin DR, Zimmern PE, Hadley HR, et al. The pathophysiology of stress incontinence. Urol Clin North Am 1985; 12: 271–8PubMedGoogle Scholar
  16. 16.
    Ouslander JG, Hepps K, Raz S, et al. Genitourinary dysfunction in a geriatric outpatient population. J Am Geriatr Soc 1986; 34(7): 507–14PubMedGoogle Scholar
  17. 17.
    William ME, Pannill III FC. Urinary incontinence in the elderly: pathophysiology, diagnosis and treatment. Ann Intern Med 1982; 97(6): 895–907Google Scholar
  18. 18.
    Skelly J, Flint AJ. Urinary incontinence associated with dementia. J Am Geriatr Soc 1995; 43: 286–94PubMedGoogle Scholar
  19. 19.
    Colling J, Ouslander J, Hadley BJ, et al. The effects of patterned urge response toileting (PURT) on urinary incontinence among nursing home residents. J Am Geriatr Soc 1992; 40: 135–41PubMedGoogle Scholar
  20. 20.
    Engel BT, Burgio LD, McCormick KA, et al. Behavioral treatment of incontinence in the long-term care setting. J Am Geriatr Soc 1990; 38: 361–3PubMedGoogle Scholar
  21. 21.
    Schnelle JF. Treatment of urinary incontinence in nursing home patients by prompted voiding. J Am Geriatr Soc 1990; 38: 356–60PubMedGoogle Scholar
  22. 22.
    Urinary Incontinence Panel. Urinary incontinence in adults: acute and chronic management. Clinical practice guideline. Rockville (MD): Agency for Health Care Policy and Research (AHCPR), Public Health Service, US Department of Health and Human Services 1996 Mar. AHCPR publication no.: 06-0682Google Scholar
  23. 23.
    Palmer MH. Urinary continence: assessment and promotion. Gaithersburg (MD): Aspen, 1996Google Scholar
  24. 24.
    Massey JA, Abrams P. Dose titration in clinical trials: an example using emepronium carrageenate in detrusor instability. Br J Urol 1986 Apr; 58(2): 125–8PubMedCrossRefGoogle Scholar
  25. 25.
    Bagger PV, Fischer-Rasmussen W, Hansen R. Emepronium carrageenate: clinical effects and urinary excretion in treatment of female urge incontinence. Scand J Urol Nephrol 1985; 19(1): 31–5PubMedCrossRefGoogle Scholar
  26. 26.
    Meyhoff HH, Gerstenberg TC, Nordling J. Placebo–the drug of choice in female motor urge incontinence? Br J Urol 1983; 55: 34–7PubMedCrossRefGoogle Scholar
  27. 27.
    Walter S, Hansen J, Hansen L, et al. Urinary incontinence in old age: a controlled clinical trial of emepronium bromide. Br J Urol 1982 Jun; 54(3): 249–51PubMedCrossRefGoogle Scholar
  28. 28.
    Williams AJ, Prematalake JK, Palmer RL. A trial of emepronium bromide for the treatment of urinary incontinence in the elderly mentally ill. Pharmatherapeutica 1981; 2(8): 539–42PubMedGoogle Scholar
  29. 29.
    Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995 Mar; 6(3): 243–62PubMedCrossRefGoogle Scholar
  30. 30.
    Szonyi G, Collas DM, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995 Jul; 24(4): 287–91PubMedCrossRefGoogle Scholar
  31. 31.
    Perico A, Triolo A, Viti G, et al. Synthesis, characterization, and analytical studies of adosupine, a potential new drug for urinary incontinence. J Pharm Sci 1994 Feb; 83(2): 137–42PubMedCrossRefGoogle Scholar
  32. 32.
    Norton P, Karram M, Wall LL, et al. Randomized double-blind trial of terodiline in the treatment of urge incontinence in women. Obstet Gynecol 1994 Sep; 84(3): 386–91PubMedGoogle Scholar
  33. 33.
    Palmer JH, Worth PH, Exton-Smith AN. Flunarizine: a once-daily therapy for urinary incontinence. Lancet 1981 Aug; II(8241): 279–81CrossRefGoogle Scholar
  34. 34.
    Lindholm P, Lose G. Terbutaline (Bricanyl) in the treatment of female urge incontinence. Urol Int 1986; 41(2): 158–60PubMedCrossRefGoogle Scholar
  35. 35.
    Taylor MC, Bates CP. A double-blind crossover trial of baclofen–a new treatment for the unstable bladder syndrome. Br J Urol 1979 Dec; 51(6): 504–5PubMedCrossRefGoogle Scholar
  36. 36.
    Sereis S, Stein M. Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourol Urodynam 1998; 17(1): 31–6CrossRefGoogle Scholar
  37. 37.
    Asplund R, Aberg HE. Micturition habits of older people: voiding frequency and urine volumes. Scand J Urol Nephrol 1992; 26: 345–9PubMedCrossRefGoogle Scholar
  38. 38.
    Asplund R, Aberg H. Desmopressin in elderly women with increased nocturnal diuresis. J Urol 1993; 72: 42–3CrossRefGoogle Scholar
  39. 39.
    Asplund R, Aberg H. Desmopressin in elderly subjects with increased nocturnal diuresis: a 2-month treatment study. Scand J Urol Nephrol 1993; 27: 77–82PubMedCrossRefGoogle Scholar
  40. 40.
    Seiler WO, Stahelin HB, Hefti U. Desmopressin reduces night urine volume in geriatric patients: implication for treatment of the nocturnal incontinence. Clin Investig 1992; 70: 619PubMedCrossRefGoogle Scholar
  41. 41.
    Janknegt RA, Zweers HHM, Delaere KPJ, et al. Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: a double blind, randomized, multicenter study. J Urol 1997; 157: 413–7CrossRefGoogle Scholar
  42. 42.
    Lepor H, Gup DI, Baumann M, et al. Comparison of alpha 1 adrenoceptors in the prostate capsule of men with symptomatic and asymptomatic benign prostatic hyperplasia. Br J Urol 1991; 67(5): 493–8PubMedCrossRefGoogle Scholar
  43. 43.
    Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with prostatic hyperplasia. N Engl J Med 1992; 327: 1185–91PubMedCrossRefGoogle Scholar
  44. 44.
    The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291–9CrossRefGoogle Scholar
  45. 45.
    Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533–9PubMedCrossRefGoogle Scholar
  46. 46.
    Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48(3): 398–405PubMedCrossRefGoogle Scholar
  47. 47.
    Walsh PC. Treatment of benign prostatic hyperplasia. N Engl J Med 1996; 335: 586–7PubMedCrossRefGoogle Scholar
  48. 48.
    Narayan P, Trachtenberg J, Lepor H, et al. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. Urology 1996; 47(4): 497–504PubMedCrossRefGoogle Scholar
  49. 49.
    Eri LM, Haug E, Tveter KJ. Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia. Br J Urol 1995; 75(3): 335–40PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Department of Geriatrics and Extended Care, NHCU (11E)Amarillo VAMCAmarilloUSA
  2. 2.Rehabilitation Research and Development Center, Atlanta Veterans Administration Medical Center, and Division of Geriatrics and Wesley Woods Geriatric CenterEmory UniversityAtlantaUSA

Personalised recommendations